Glucose-6-phosphate dehydrogenase deficiency
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
acute hemolysis
supportive care plus folic acid
Affected patients should be encouraged to maintain a good fluid intake and to eat a light diet, as nausea is common.
A hematology consult is warranted once hemolytic anemia is diagnosed.
Folic acid is required to supply increased RBC production.
Primary options
folic acid (vitamin B9): 1-5 mg orally once daily for 14-21 days
blood transfusion
Treatment recommended for ALL patients in selected patient group
A hematology consult is warranted once hemolytic anemia is diagnosed.
Packed RBC transfusion is recommended in those with severe or symptomatic anemia.
Absolute Hb threshold for transfusion differs based on age and comorbidities. Blood from G6PD-deficient donors should not be used for neonatal transfusions and should certainly not be used when transfusing neonates with G6PD deficiency.[39]Renzaho AM, Husser E, Polonsky M. Should blood donors be routinely screened for glucose-6-phosphate dehydrogenase deficiency? A systematic review of clinical studies focusing on patients transfused with glucose-6-phosphate dehydrogenase-deficient red cells. Transfus Med Rev. 2014 Jan;28(1):7-17. http://www.ncbi.nlm.nih.gov/pubmed/24289973?tool=bestpractice.com
blood transfusion and renal support
Treatment recommended for ALL patients in selected patient group
Erythropoietin can potentially assist in patients with inadequate endogenous erythropoietin levels, such as patients with severe kidney disease.
A hematology consult is warranted once hemolytic anemia is diagnosed.
Packed RBC transfusion is recommended in those with severe or symptomatic anemia.
Blood from G6PD-deficient donors should not be used for neonatal transfusions and should certainly not be used when transfusing neonates with G6PD deficiency.[39]Renzaho AM, Husser E, Polonsky M. Should blood donors be routinely screened for glucose-6-phosphate dehydrogenase deficiency? A systematic review of clinical studies focusing on patients transfused with glucose-6-phosphate dehydrogenase-deficient red cells. Transfus Med Rev. 2014 Jan;28(1):7-17. http://www.ncbi.nlm.nih.gov/pubmed/24289973?tool=bestpractice.com
In patients with impaired renal function receiving blood transfusions, additional measures may be required.
Hemoglobinuria can cause acute renal damage.
Dialysis may be required to support the patient until renal function recovers. As the renal injury is acute, dialysis is not likely to be required long-term.
Primary options
epoetin alfa: consult specialist for guidance on dose
neonates with prolonged indirect hyperbilirubinemia
phototherapy
Neonatal jaundice should be managed by pediatricians familiar with the appropriate guidelines.[42]Kemper AR, Newman TB, Slaughter JL, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022 Sep 1;150(3):e2022058859. https://www.doi.org/10.1542/peds.2022-058859 http://www.ncbi.nlm.nih.gov/pubmed/35927462?tool=bestpractice.com
Phototherapy uses light energy to cause photochemical reactions to transform bilirubin into isomers that are less lipophilic and more easily excretable, making breakdown products that do not require conjugation in the liver. The most effective wavelengths are from 425 to 490 nm.[16]Maisels MJ. Neonatal jaundice. Pediatr Rev. 2006 Dec;27(12):443-54. http://www.ncbi.nlm.nih.gov/pubmed/17142466?tool=bestpractice.com
Double-light phototherapy is more effective than single-light or fiberoptic phototherapy.[43]Holtrop PC, Ruedisueli K, Maisels, MJ. Double versus single phototherapy in low birth weight newborns. Pediatrics. 1992 Nov;90(5):674-7. http://www.ncbi.nlm.nih.gov/pubmed/1408537?tool=bestpractice.com
Fiberoptic phototherapy is an alternative to conventional phototherapy in term neonates with physiologic jaundice.[44]Mills JF, Tudehope D. Fibreoptic phototherapy for neonatal jaundice. Cochrane Database Syst Rev. 2001 Jan 22;2001(1):CD002060.
https://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002060/full
http://www.ncbi.nlm.nih.gov/pubmed/11279748?tool=bestpractice.com
[ ]
How does fiberoptic phototherapy compare with conventional phototherapy for neonates with jaundice?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.2175/fullShow me the answer
exchange transfusion
Treatment recommended for ALL patients in selected patient group
In the face of acute ongoing hemolysis or markedly elevated bilirubin levels, exchange transfusion should be considered early on.
Neonatal jaundice should be managed by pediatricians familiar with the appropriate guidelines.
Phototherapy is continued while waiting to start the procedure, stopped while doing the transfusion, and restarted as soon as the exchange transfusion is completed.
The rationale is to remove the unconjugated bilirubin by doing a double-volume exchange transfusion, which should allow the bilirubin to move out of the brain tissue and hence decrease the risk of neurologic toxicities.
There is insufficient evidence to support or refute the use of single-volume exchange transfusion, as opposed to double-volume exchange transfusion, in jaundiced newborns.[45]Thayyil S, Milligan DW. Single versus double volume exchange transfusion in jaundiced newborn infants. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004592. https://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004592.pub2/full http://www.ncbi.nlm.nih.gov/pubmed/17054210?tool=bestpractice.com
Some specialists recommend the use of 5% albumin before the exchange transfusion in an attempt to bind unconjugated (free) bilirubin.
The major potential complications of the procedure include electrolyte disturbances, bleeding, infection, cardiac arrhythmias, thrombosis with embolization, necrotizing enterocolitis, and graft-versus-host disease.
chronic nonspherocytic hemolytic anemia
supportive care plus folic acid
A hematology consult is warranted once hemolytic anemia is diagnosed.
Packed RBC transfusion is restricted to symptomatic anemia.
Folic acid is required to supply increased RBC production.
Primary options
folic acid (vitamin B9): 1-5 mg orally once daily
blood transfusion
Treatment recommended for ALL patients in selected patient group
A hematology consult is warranted once hemolytic anemia is diagnosed.
Packed RBC transfusion is restricted to symptomatic anemia.
Absolute Hb threshold for transfusion differs based on age and comorbidities. Blood from G6PD-deficient donors should not be used for neonatal transfusions and should certainly not be used when transfusing neonates with G6PD deficiency.[39]Renzaho AM, Husser E, Polonsky M. Should blood donors be routinely screened for glucose-6-phosphate dehydrogenase deficiency? A systematic review of clinical studies focusing on patients transfused with glucose-6-phosphate dehydrogenase-deficient red cells. Transfus Med Rev. 2014 Jan;28(1):7-17. http://www.ncbi.nlm.nih.gov/pubmed/24289973?tool=bestpractice.com
splenectomy
Treatment recommended for SOME patients in selected patient group
Splenectomy may be considered for those with significant extravascular hemolysis, marked splenomegaly, or persistent severe anemia that is interfering with growth, development, or normal activity. This may result in a significant decrease in hemolysis.
Cholecystectomy may be considered at the same time if gallstones are present.
Patients who are about to undergo splenectomy should receive appropriate immunizations (against pneumococcus, meningococcus, and Haemophilus influenzae) and start long-term antibiotic prophylaxis to protect against infection by encapsulated bacterial organisms.[46]Davies JM, Lewis MP, Wimperis J, et al. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. Br J Haematol. 2011 Nov;155(3):308-17. http://www.ncbi.nlm.nih.gov/pubmed/21988145?tool=bestpractice.com CDC: ACIP vaccine recommendations and guidelines Opens in new window
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer